GlassScriptPhysician profile
Shenika N Garner
NPI 1104315183
$3,696.71
in general payments reported to CMS, 2019-2025
41 companies · $1,640 in 2025
The $1,640 reported for 2025 was more than what 95% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $194 · 2023: $711 · 2024: $1,152 · 2025: $1,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,503.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $488.82 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Eisai INC. | $464.83 | 2022-2025 | |
| Glaxosmithkline, LLC. | $376.85 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $347.45 | 2022-2025 | Lynparza, Tagrisso, Calquence |
| Janssen Biotech, INC. | $258.13 | 2023-2025 | Rybrevant, Tecvayli, Darzalex |
| Daiichi Sankyo INC. | $211.68 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Coherus Oncology, INC. | $170.77 | 2022-2025 | Loqtorzi |
| Bayer Healthcare Pharmaceuticals INC. | $111.95 | 2022-2025 | |
| Genentech USA, INC. | $100.70 | 2024-2025 | Polivy, Venclexta, Itovebi |
| Novartis Pharmaceuticals Corporation | $93.02 | 2023-2024 | |
| Genzyme Corporation | $74.85 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $72.22 | 2023-2025 | Ultomiris |
| Aimmune Therapeutics, INC. | $66.92 | 2024-2025 | Zenpep |
| Pfizer INC. | $61.42 | 2023-2025 | |
| Deciphera Pharmaceuticals INC. | $57.76 | 2023-2025 | Qinlock, Romvimza |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $55.00 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $54.56 | 2023-2025 | |
| Astellas Pharma US INC | $51.64 | 2024 | Veozah |
| Rigel Pharmaceuticals, INC. | $50.40 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Ethicon US, LLC | $48.23 | 2024-2025 | Surgicel Nu-Knit, Vistaseal, Surgiflo Hemostatic Matrix |
| Incyte Corporation | $37.62 | 2023-2025 | Monjuvi, Pemazyre, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $33.00 | 2024 | Fruzaqla |
| Invivyd INC | $31.71 | 2025 | Pemgarda |
| Seagen INC. | $27.94 | 2023 | Tivdak |
| Karyopharm Therapeutics INC. | $26.90 | 2022 | |
| Iovance Biotherapeutics, INC. | $26.32 | 2025 | Amtagvi |
| Servier Pharmaceuticals LLC | $25.38 | 2025 | |
| Tersera Therapeutics LLC | $25.06 | 2023 | Xermelo |
| Adaptive Biotechnologies Corporation | $23.75 | 2025 | Clonoseq |
| Beone Medicines USA, INC. | $22.96 | 2025 | Brukinsa |
| Acrotech Biopharma INC. | $22.76 | 2025 | Beleodaq |
| Amgen INC. | $20.82 | 2022 | |
| Myriad Genetic Laboratories, INC. | $19.61 | 2023 | Mychoice Cdx |
| Puma Biotechnology, INC. | $18.29 | 2024 | |
| Stemline Therapeutics INC. | $17.59 | 2024 | Orserdu |
| Mimedx Group, INC. | $17.28 | 2025 | |
| On Target Laboratories, INC | $17.24 | 2025 | Cytalux |
| Sumitomo Pharma America, INC. | $17.03 | 2023 | Orgovyx |
| Immunogen, INC. | $16.92 | 2023 | Elahere |
| Fresenius Kabi USA, LLC | $15.87 | 2025 | Stimufend |
| Baxter Healthcare | $15.46 | 2023 | Floseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shenika Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.